ALK and neuroblastoma: from molecular genetics to clinics
https://doi.org/10.21682/2311-1267-2019-6-2-54-60
Abstract
Neuroblastoma (NB) is the most common extracranial embryonic tumor in children with a variety of molecular biological and clinical characteristics. There is no single molecular genetic mechanism involved in the pathogenesis of NB, which determines its heterogeneity. Pathogenetically important event in the development of NB are aberrations of ALK gene (Anaplastic lymphoma kinase), which are found in 70 % of patients with familial form of NB and in 7– 10 % of patients with sporadic cases. ALK oncogene encodes a receptor of the same name, expressed on the membrane of cells of the central and peripheral nervous system, which is in the activated state in NB. The negative effect of ALK gene anomalies on the prognosis in patients with different risk groups of NB is described. ALK gene aberrations are more often detected duringrelapse and refractory course of the disease. Because of its tissue specificity, ALK protein is an ideal target for targeted therapy. This article presents a literature review of the role of ALK in NB.
About the Authors
N. A. Andreeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Pediatric Oncologist, Department of Clinical Oncology Dmitry Rogachev
1 Samory Mashela St., Moscow, 117997
A. E. Druy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Laboratory of Cytogenetics and Molecular Genetics
1 Samory Mashela St., Moscow, 117997
T. V. Shamanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Academic Secretary of the Institute of Oncology, Radiology and Nuclear Medicine
1 Samory Mashela St., Moscow, 117997
D. Yu. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of the Department of Clinical Oncology and Department of Embryonic Tumor Research & Deputy Director of the Institute of Oncology, Radiology and Nuclear Medicine
1 Samory Mashela St., Moscow, 117997
S. R. Varfolomeeva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Deputy General Director – Director of the Institute of Management and Translational Medicine at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia, Executive Director of Regional Public Organization National Society of Pediatric Hematologists and Oncologists
1 Samory Mashela St., Moscow, 117997
References
1. Schulte J.H., Schulte S., Heukamp L.C., Astrahantseff K., Stephan H., Fischer M., Schramm A., Eggert A. Targeted therapy for neuroblastoma: ALK inhibitors. Klin Padiatr 2013;225(6):303–8. doi: 10.1055/s-0033-1357132.
2. Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985–93. doi: 10.1002/pbc.24433.
3. Johnsen J.I., Dyberg C., Fransson S., Wickstrom M. Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacological Research 2018;131:164–76. doi: 10.1016/j.phrs.2018.02.023.
4. Whittle S.B., Smith V., Doherty E., Zhao S., McCarty S., Zage P.E. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017;17(4):369–86. doi: 10.1080/14737140.2017.1285230.
5. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930–5. doi: 10.1038/nature07261.
6. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455(7215):971–4. doi: 10.1038/nature07399.
7. George R.E., Sanda T., Hanna M., Fröhling S., Luther W. 2nd, Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975–8. doi: 10.1038/nature07397.
8. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967–70. doi: 10.1038/nature07398.
9. Tolbert V.P., Coggins G.E., Maris J.M. Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev 2017;42:81–90. doi: 10.1016/j.gde.2017.03.008.
10. Catalogue of somatic mutations in cancer (GRCh38 COSMIC v.87). URL: https://cancer.sanger.ac.uk/cosmic/browse/tissue?hn=neuroblastoma&in=t&sn=autonomic_ganglia&ss=all
11. Padovan-Merhar O.M., Raman P., Ostrovnaya I., Kalletla K., Rubnitz K.R., Sanford E.M., Ali S.M., Miller V.A., Mossé Y.P., Granger M.P., Weiss B., Maris J.M., Modak S. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLоS Genetics 2016;12(12):e1006501. doi: 10.1371/journal.pgen.1006501.
12. Trigg R.M., Turner S.D. ALK in neuroblastoma: biological and therapeutic implications. Cancers (Basel) 2018;10(4):113. doi: 10.3390/cancers10040113.
13. Buechner J., Tømte E., Haug B.H., Henriksen J.R., Løkke C., Flægstad T., Einvik C. Tumour-suppressor microRNAs let-7 and mir101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011;105(2):296-303. doi: 10.1038/bjc.2011.220.
14. Hallberg B., Palmer R.H. The role of the ALK receptor in cancer biology. Ann Oncol 2016;27(Suppl 3):iii4–iii15. doi: 10.1093/annonc/mdw301.
15. Eleveld T.F., Oldridge D.A., Bernard V., Koster J., Colmet Daage L., Diskin S.J., Schild L., Bentahar N.B., Bellini A., Chicard M., Lapouble E., Combaret V., Legoix-Né P., Michon J., Pugh T.J., Hart L.S., Rader J., Attiyeh E.F., Wei J.S., Zhang S., Naranjo A., Gastier-Foster J.M., Hogarty M.D., Asgharzadeh S., Smith M.A., Guidry Auvil J.M., Watkins T.B., Zwijnenburg D.A., Ebus M.E., van Sluis P., Hakkert A., van Wezel E., van der Schoot C.E., Westerhout E.M., Schulte J.H., Tytgat G.A., Dolman M.E., Janoueix-Lerosey I., Gerhard D.S., Caron H.N., Delattre O., Khan J., Versteeg R., Schleiermacher G., Molenaar J.J., Maris J.M. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 2015;47(8):864–71. doi: 10.1038/ng.3333.
16. Bresler S.C., Weiser D.A., Huwe P.J., Park J.H., Krytska K., Ryles H., Laudenslager M., Rappaport E.F., Wood A.C., McGrady P.W., Hogarty M.D., London W.B., Radhakrishnan R., Lemmon M.A., Mossé Y.P. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26(5):682–94. doi: 10.1016/j.ccell.2014.09.019.
17. Passoni L., Longo L., Collini P., Coluccia A.M., Bozzi F., Podda M., Gregorio A., Gambini C., Garaventa A., Pistoia V., Del Grosso F., Tonini G.P., Cheng M., Gambacorti-Passerini C., Anichini A., Fossati-Bellani F., Di Nicola M., Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69(18):7338–46. doi: 10.1158/0008-5472.CAN-08-4419.
18. Schulte J.H., Bachmann H.S., Brockmeyer B., Depreter K., Oberthür A., Ackermann S., Kahlert Y., Pajtler K., Theissen J., Westermann F., Vandesompele J., Speleman F., Berthold F., Eggert A., Brors B., Hero B., Schramm A., Fischer M. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011;17(15):5082–92. doi: 10.1158/1078-0432.CCR-10-2809.
19. Ogura T., Hiyama E., Kamei N., Kamimatsuse A., Ueda Y., Ogura K. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma. J Pediatr Surg 2012;47(10),1789–96. doi: 10.1016/j.jpedsurg.2012.05.007.
20. Mosse Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J., Rolland D., Balis F.M., Maris J.M., Weigel B.J., Ingle A.M., Ahern C., Adamson P.C., Blaney S.M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 2013;14(6):472–80. Обзоры лит ерат уры || Li terature revi ews doi: 10.1016/S1470-2045(13)70095-0.
21. Bellini A., Bernard V., Leroy Q., Rio Frio T., Pierron G., Combaret V., Lapouble E., Clement N., Rubie H., Thebaud E., Chastagner P., Defachelles A.S., Bergeron C., Buchbinder N., Taque S., Auvrignon A., Valteau-Couanet D., Michon J., Janoueix-Lerosey I., Delattre O., Schleiermacher G. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res 2015;21(21):4913–21. doi: 10.1158/1078-0432.CCR-15-0423.
22. De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., Lakeman A., Vandesompele J., Hoebeeck J., Van Maerken T., De Paepe A., Laureys G., Schulte J.H., Schramm A., Van Den Broecke C., Vermeulen J., Van Roy N., Beiske K., Renard M., Noguera R., Delattre O., Janoueix-Lerosey I., Kogner P., Martinsson T., Nakagawara A., Ohira M., Caron H., Eggert A., Cools J., Versteeg R., Speleman F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2011;16(17): 4353-62. doi: 10.1158/1078-0432.CCR-09-2660.
23. Berry T., Luther W., Bhatnagar N., Jamin Y., Poon E., Sanda T., Pei D., Sharma B., Vetharoy W.R., Hallsworth A., Ahmad Z., Barker K., Moreau L., Webber H., Wang W., Liu Q., Perez-Atayde A., Rodig S., Cheung N.K., Raynaud F., Hallberg B., Robinson S.P., Gray N.S., Pearson A.D., Eccles S.A., Chesler L., George R.E. The ALK (F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012;22(1):117–30. doi: 10.1016/j.ccr.2012.06.001.
24. Lopez-Delisle L., Pierre-Eugene C., Louis-Brennetot C., Surdez D., Raynal V., Baulande S., Boeva V., Grossetête-Lalami S., Combaret V., Peuchmaur M., Delattre O., Janoueix-Lerosey I. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. Oncogene 2018;37(11):1417–29. doi:10.1038/s41388-017-0039-5.
25. Matthay K.K., George R.E., Yu A.L. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012;18(10):2740–53. doi: 10.1158/1078-0432.CCR-11-1939.
26. Carpenter E.L., Mossé Y.P. Targeting ALK in neuroblastoma – preclinical and clinical advancement. Nat Rev Clin Oncol 2012;9(7):391–9. doi: 10.1038/nrclinonc.2012.72.
27. Rodig S.J., Shapiro G.I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010;11(12):1477–90. PMID: 21154129.
28. Felkali L., Banusz R., Kovalszky I., Sápi Z., Garami M., Papp G., Karászi K., Varga E., Csóka M. The presence of ALK alterations and clinical relevance of crizotinib treatment in pediatric solid tumors. Pathol Oncol Res 2019;25(1):217–24. doi: 10.1007/s12253-017-0332-1.
29. Azarova A.M., Gautam G., George R.E. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011;21(4):267–75. doi: 10.1016/j.semcancer.2011.09.005.
30. Bresler S.C., Wood A.C., Haglund E.A., Courtright J., Belcastro L.T., Plegaria J.S., Cole K., Toporovskaya Y., Zhao H., Carpenter E.L., Christensen J.G., Maris J.M., Lemmon M.A., Mosse Y.P. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3(108):108ra114. doi: 10.1126/scitranslmed.3002950.
31. Infarinato N.R., Park J.H., Krytska K., Ryles H.T., Sano R., Szigety K.M., Li Y., Zou H.Y., Lee N.V., Smeal T., Lemmon M.A., Mossé Y.P. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov 2016;6(1):96–107. doi: 10.1158/2159-8290.CD-15-1056.
32. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4(6):662–73. doi: 10.1158/2159-8290.CD-13-0846.
33. Clinicaltrials.gov. URL: https://clinicaltrials.gov/ct2/results?term=neuroblastoma+alk&age_v=&age=0&gndr=&type=&rslt=&Search=Apply
34. Krytska K., Ryles H.T., Sano R., Raman P., Infarinato N.R., Hansel T.D., Makena M.R., Song M.M., Reynolds C.P., Mossé Y.P. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin Cancer Res 2016;22(4):948–60. doi: 10.1158/1078-0432.CCR-15-0379.
35. Zhang L., Wu B., Baruchel S. Oral metronomic topotecan sensitizes crizotinib antitumor activity in ALKF1174L drug-resistant neuroblastoma preclinical models. Transl Oncol 2017;10(4):604–11. doi: 10.1016/j.tranon.2017.04.008.
36. A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL). [Электронный ресурс]: http://ClinicalTrials.gov. Identifier: NCT03126916.
Review
For citations:
Andreeva N.A., Druy A.E., Shamanskaya T.V., Kachanov D.Yu., Varfolomeeva S.R. ALK and neuroblastoma: from molecular genetics to clinics. Russian Journal of Pediatric Hematology and Oncology. 2019;6(2):54-60. (In Russ.) https://doi.org/10.21682/2311-1267-2019-6-2-54-60
Views:
84888
Email this article 